Do preclinical Alzheimer's disease criteria work?

The Lancet Neurology

Volumn 12, Issue 10, 2013, Pages 933-935

  Petersen, Ronald C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; BAPINEUZUMAB; BIOLOGICAL MARKER; SOLANEZUMAB;

AGING; ALZHEIMER DISEASE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; DEMENTIA; DISEASE COURSE; EARLY DIAGNOSIS; HUMAN; INTERVENTION STUDY; LETTER; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; SECONDARY PREVENTION; VALIDITY;

ALZHEIMER DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; PRODROMAL SYMPTOMS;

EID: 84884151064     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70217-5     Document Type: Letter

References (14)

1. Jack CR, Albert MS, Knopman DS, et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:257-262.
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:280-292.
3. Jack CR, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
4. Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
5. Jack CR, Knopman DS, Weigand SD, et al. An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease. Ann Neurol 2012, 71:765-775.
6. Knopman DS, Jack CR, Wiste HJ, et al. Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease. Neurology 2012, 78:1576-1582.
7. Vos SJB, Xiong C, Visser PJ, et al. Preclinical Alzheimer's disease and its outcome: a longitudinal cohort study. Lancet Neurol 2013, published online Sept 2. http://dx.doi.org/10.1016/S1474-4422(13)70194-7.
8. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010, 9:1118-1127.
9. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging and Alzheimer's Association Workgroup. Alzheimers Dement 2011, 7:270-279.
10. Petersen RC Mild cognitive impairment as a diagnostic entity. J Intern Med 2004, 256:183-194.
11. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology 2010, 74:201-209.
12. Rowe CC, Ellis KA, Rimajova M, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010, 31:1275-1283.
13. Visser PJ, Verhey F, Knol DL, et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 2009, 8:619-627.
14. Petersen RC, Aisen P, Boeve BF, et al. Criteria for mild cognitive impairment due to alzheimer's disease in the community. Ann Neurol 2013, published online May 20. 10.1002/ana.23931.